$198.64
0.00% yesterday
NYSE, Aug 12, 10:09 pm CET
ISIN
US00287Y1091
Symbol
ABBV

AbbVie Stock price

$198.64
+7.12 3.72% 1M
+5.64 2.92% 6M
+20.94 11.78% YTD
+8.46 4.45% 1Y
+56.04 39.30% 3Y
+103.13 107.98% 5Y
+129.89 188.93% 10Y
+163.64 467.54% 20Y
NYSE, Closing price Tue, Aug 12 2025
+0.00 0.00%
ISIN
US00287Y1091
Symbol
ABBV
Industry

Key metrics

Basic
Market capitalization
$351.0b
Enterprise Value
$415.0b
Net debt
$64.0b
Cash
$6.5b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
94.6 | 16.0
P/S
6.0 | 5.7
EV/Sales
7.1 | 6.8
EV/FCF
22.8
P/B
negative
Dividends
DPS
$6.29
Yield 1Y | 5Y
3.2% | 4.2%
Growth 1Y | 5Y
5.0% | 7.5%
Payout 1Y | 3Y
263.2% | 153.2%
Increased
13 Years
Financials (TTM | estimate)
Revenue
$58.3b | $61.2b
EBITDA
$26.5b | $28.8b
EBIT
$18.2b | $27.7b
Net Income
$3.7b | $21.9b
Free Cash Flow
$18.2b
Growth (TTM | estimate)
Revenue
6.1% | 8.7%
EBITDA
8.0% | 15.6%
EBIT
13.8% | 68.0%
Net Income
-29.7% | 416.3%
Free Cash Flow
2.6%
Margin (TTM | estimate)
Gross
70.9%
EBITDA
45.5% | 47.0%
EBIT
31.3%
Net
6.4% | 35.7%
Free Cash Flow
31.3%
Financial Health
Equity Ratio
2.5%
Return on Equity
127.5%
ROCE
18.7%
ROIC
-
Debt/Equity
-385.1
More
EPS
$2.1
FCF per Share
$10.3
Short interest
0.9%
Employees
55k
Rev per Employee
$1.0m
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a AbbVie forecast:

23x Buy
68%
11x Hold
32%

Analyst Opinions

34 Analysts have issued a AbbVie forecast:

Buy
68%
Hold
32%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
58,328 58,328
6% 6%
100%
- Direct Costs 16,956 16,956
8% 8%
29%
41,372 41,372
13% 13%
71%
- Selling and Administrative Expenses 14,562 14,562
11% 11%
25%
- Research and Development Expense 8,602 8,602
14% 14%
15%
26,509 26,509
8% 8%
45%
- Depreciation and Amortization 8,270 8,270
3% 3%
14%
EBIT (Operating Income) EBIT 18,239 18,239
14% 14%
31%
Net Profit 3,723 3,723
30% 30%
6%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Positive
Seeking Alpha
about 2 hours ago
AbbVie Inc.'s Q2 2025 results highlight Skyrizi and Rinvoq's dominance, replacing Humira and driving impressive revenue growth, with both drugs exceeding expectations. The company's aggressive neuroscience expansion, including a potential Gilgamesh Pharmaceuticals acquisition, aligns with its strategy to diversify and secure future blockbuster assets. Financially, AbbVie maintains strong perfor...
Neutral
PRNewsWire
about 6 hours ago
New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade Construction will begin in fall 2025 with the site expected to be fully operational in 2027 Furthers AbbVie's long-...
Positive
The Motley Fool
2 days ago
Short-term market fluctuations can be stressful, there's no doubt about that. The good news is, long-term investors are in a better position to weather these storms.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 55,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today